Tobamovirus-based virus-like particles and vaccines

US11285204B2 · office US · priority 2017-09-22 · published 2022-03-29

The resulting vaccine was able to confer high level protection that was superior to the soluble CSP and it may not require complex adjuvants that contain potentially expensive and reactogenic immune modulators in humans. In one embodiment, a novel malaria vaccine based on this concept is described.

Inventor: Sheetij Dutta · Assignee: The Government Of The United States, As Represen

Open the patent document · source query “malaria vaccine”